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Significance 
Traditional analysis of clinical trials precludes a mechanistic understanding of drug 
actions. This is further compounded by the use of outcome measures in clinical trials 
that may not relate directly to the mechanism of action of the medication under study. 
Here we applied causal structural equation models to the double-blind randomised 
controlled trial of simvastatin in secondary progressive multiple sclerosis to help inform 
us of key pathways underlying treatment effects. Our results suggest that beneficial 
effects of simvastatin on reducing the rate of brain atrophy and slowing the 
deterioration of disability are independent of serum cholesterol reduction. Our work 
demonstrates that structural models can elucidate the statistical pathways underlying 
treatment effects in clinical trials of poorly understood neurodegenerative disorders, 
such as progressive multiple sclerosis. 
   
  
Abstract 
Understanding the mode of action of drugs is a challenge with conventional methods 
in clinical trials. Here we aimed to explore whether the simvastatin effects on brain 
atrophy and disability in secondary progressive multiple sclerosis (SPMS) are 
mediated by reducing cholesterol or are independent of cholesterol, using mechanistic 
computational models. We applied structural equation models to the MS-STAT trial in 
which 140 patients with SPMS were randomised to receive placebo or simvastatin (80 
mg/day). At baseline, after one and two years, patients underwent brain magnetic 
resonance imaging; their cognitive and physical disability were assessed on the Block 
Design test and Expanded Disability Status Scale (EDSS), and serum total cholesterol 
levels were measured. We used SIENA to calculate the percentage brain volume 
change (brain atrophy). We compared two models to select the most likely one: a 
cholesterol-dependent model with a cholesterol-independent model. The cholesterol-
independent model was the most likely option. When we deconstructed the total 
treatment effect into indirect effects, which were mediated by brain atrophy, and direct 
effects, simvastatin had a direct effect (independent of serum cholesterol) on both the 
EDSS, which explained 69% of the overall treatment effect on EDSS, and brain 
atrophy, which, in turn, was responsible for 31% of the total treatment effect on EDSS 
(beta=-0.037, 95% credible interval [CI]=-0.075, -0.010). This study supports the 
hypothesis that simvastatin’s beneficial effects in MS are independent of its effect on 
circulating cholesterol, implicating a role for upstream intermediate metabolites of the 
cholesterol synthesis pathway. Importantly, it demonstrates that computational models 
can elucidate the causal architecture underlying treatment effects in clinical trials of 
progressive MS. 
 
  
Introduction 
 
Understanding mechanisms underpinning progression in multiple sclerosis (MS) is a 
significant challenge and a major research focus(1) . Therefore, the mode of action of 
potential therapies for progressive MS is difficult to elicit. This is further compounded 
by the use of outcome measures in clinical trials that may not relate directly to the 
mechanism of action of the medication under study (1). The challenge of 
understanding the mode of action of a medication is exemplified by the simvastatin 
trial, a phase 2 trial for secondary progressive MS (2), in which MRI measures of 
atrophy and clinical disability showed beneficial effects. The fundamental question as 
to whether simvastatin’s beneficial effects on clinical outcomes and brain atrophy were 
mediated by lowering peripheral cholesterol levels was impossible to answer (3).  
 
Mechanistic computational methods can elucidate the most plausible chain of events, 
by simultaneous analysis of multi-modal data; these models assess hypothesised 
causal (and statistical) associations linking intermediate variables to outcomes of 
interest (4). They have been employed in clinical trials of Alzheimer’s disease (5), 
neurocognitive ageing (6), and more extensively in social sciences (7). Applying 
multivariate mechanistic models to the simvastatin trial allows a quantitative 
comparison of the statistical pathways resulting in the observed effects of simvastatin 
on clinical outcomes clarifying the mechanisms underpinning its effect. An improved 
understanding of these statistical pathways will show that this methodology can be 
extended to other trials to obtain insights into the mechanisms through which 
experimental therapies provide clinical benefit.  
 
In this study, we re-analysed the MS-STAT trial data and modelled hypothesised 
causal associations by which simvastatin leads to changes in brain atrophy, clinical 
and cognitive outcome measures, either directly or indirectly via changes in peripheral 
cholesterol level. We tested the hypothesis that the reduction in serum cholesterol 
levels mediated the impact of simvastatin on brain atrophy and on disability against 
the alternative hypothesis that simvastatin effects were independent of peripheral 
cholesterol level. A subsidiary aim was to investigate whether the effect of simvastatin 
on brain atrophy was targeting specific regions.  
Material and Methods 
Participants 
This was a post hoc study that included participants of the MS-STAT trial 
[ClinicalTrials.gov registration number: NCT00647348](2). MS-STAT was a phase 2 
double-blind randomised controlled trial whose primary and pre-planned analyses 
have been reported previously (2, 8). Briefly, the eligibility criteria were: (i) age 
between 18-65 years, (ii) Expanded Disability Status Scale (EDSS)(9) of between 4.0 
and 6.5, (iii) fulfilling revised 2005 McDonald criteria (10), and (iv) secondary 
progressive MS defined by clinically-confirmed disability worsening over the preceding 
two years. Detailed eligibility criteria are available elsewhere (2). 
 
Imaging protocol  
Patients were scanned at each visit (three visits in total) with 3D T1-weighted, double-
echo proton density (PD) and T2-weighted MRI at two imaging centres in the UK with 
1.5 Tesla and 3 Tesla scanners. The same scanner and imaging protocol were used 
for an individual participant throughout the trial. “Scanner” was a minimisation variable 
(as explained above) between treatment and placebo groups. Acquisition protocols 
are reported elsewhere (2). 
 
Clinical and cognitive outcomes 
Patients underwent comprehensive clinical and cognitive assessments. Here, we 
studied those outcomes that had shown significant (or marginally significant) changes 
in previous reports (2, 8), which were the following: the total cholesterol level, EDSS, 
Multiple Sclerosis Impact Scale 29v2 (total score and physical subscale)(11), 
Wechsler Abbreviated Test of Intelligence (WASI) Block Design test (T-score)(12), 
Paced-auditory serial addition test (PASAT) (13), and Frontal Assessment Battery 
(FAB)(14).  
 
Image analysis 
We performed image analysis based on our established pipeline for patients with MS 
which is similar to what we have previously reported (15). Our goals were to extract 
regional volumes, T2 lesion masks and the whole brain percentage volume change 
with SIENA (16). Briefly, the pipeline included N4-bias field correction of T1-weighted 
scans to reduce intensity inhomogeneity (17), constructing a symmetric within-subject 
template for unbiased atrophy calculation (18), rigid transformation of T1, PD, and T2 
sequences to the within-subject unbiased symmetric space, automatic longitudinal 
lesion segmentation of visible T2 lesions with Bayesian Model Selection (BaMoS) (19, 
20), manual editing of these lesion masks and quality assurance with the 3D-Slicer 
software, filling of hypointense lesions in T1 scans (21), and brain segmentation and 
parcellation with Geodesic Information Flows (GIF) software (22). Technical details 
are given in the Supplemental Methods. Outputs of this pipeline were the following: 
(i) percentage whole brain volume change (SIENA PBVC), (ii) T2 lesion masks, and 
(iii) regional brain volumes according to Neuromorphometrics' atlas, which is similar 
to the Desikan-Killiany-Tourville (23) atlas available at 
http://braincolor.mindboggle.info; for each region we summed volumes of the left and 
right hemispheres. 
 
Statistical analysis 
We employed separate mixed-effects models to calculate the differences in the rate 
of changes in brain volume loss, EDSS and cognitive scores (PASAT, Frontal 
Assessment Battery and Block Design T-score) over time between the two arms of 
the trial. The aim of these analyses, which are different from the statistical tests carried 
out in the previous publication of this trial (2, 8), was to identify variables that showed 
a significant difference in their rates of change between treated and placebo arms and 
can be entered in the subsequent multivariate analysis (see below). Demographic and 
disease characteristics and the details of these mixed-effect models and the 
corresponding results are given in the Supplemental Material.  
Multivariate analysis 
We performed multivariate analyses in the following steps: 
(i) Variable selection using the above (mixed-effects) univariate analyses: to 
limit the analysis to measures with significant rates of change. 
(ii) Model construction: to formulate mechanistic hypotheses as structured 
statistical models. 
(iii) Model selection: to choose the most likely hypothesis. 
(iv) Parameter estimation: to quantify, in the most likely model, pathways 
between serum cholesterol levels, brain atrophy, cognitive, patient-reported 
outcome measure, and clinical variables. 
 
Variable selection and model construction  
We implemented multivariate analysis with structural equation modelling. Specifically, 
we fit a series of path models, which test whether a set of causal pathways is 
compatible with the observed associations. We used Lavaan package version 0.5-23 
(24) in R. Structural equation models allow simultaneous fitting of several regression 
models to quantify statistical pathways between variables. We included outcomes 
from the univariate analyses (explained above) that had significant differences in their 
rate of change between placebo and simvastatin groups. Since nuisance variables 
(age, gender, and centre) did not affect the above univariate analyses, we did not 
include them in multivariate models. We only entered the physical subtest of Multiple 
Sclerosis Impact Scale-29v2 (instead of the total score) in structural equation models, 
because changes in this subtest drove the change in total score. Similarly, we entered 
the block design test because the mixed-effects models showed a significant 
difference in this test between the treated and the placebo arm (see Supplemental 
Material). We calculated the difference between baseline and second-year values for 
each variable and divided it by two. We refer to this as the annualised change 
throughout this manuscript.  
We hypothesised two a priori models to explain relationships between these variables 
according to the literature (25, 26) and on the basis of our opinion. The first is a 
cholesterol-mediated model, in which the effects of simvastatin on clinical measures 
(both physical and cognitive) and brain atrophy are mediated by changes in cholesterol 
(Figure 1, (A)). The second is a cholesterol-independent model, in which simvastatin 
has a direct effect on the clinical and MRI outcome measures, independent of its effect 
on serum cholesterol levels (Figure 1, (B)). In both models, the rate of brain atrophy 
development has a direct effect on clinical change, as measured by the EDSS, Block 
Design and the Multiple Sclerosis Impact Scale-29v2 (MSIS-29v2) (Figure 1). In both 
models, we included MSIS-29v2 (physical sub-score) the last variable in the cascade 
of events, because it is a subjective patient-reported questionnaire of physical ability 
expected to reflect the impact that clinical and cognitive impairment has on patient’s 
quality of life.  
  
 
 
Model selection and parameter estimation 
We fitted both the cholesterol-mediated and cholesterol-independent model (shown in 
Figure 1) using full-information maximum likelihood to adjust for missingness, and 
with the robust standard-errors to account for non-normality (e.g., EDSS). We 
assessed the goodness-of-fit for each model and reported the parameters for the most 
likely model. To evaluate overall fit of a model we used the comparative fit index (CFI; 
compares the fit of the model with a model with uncorrelated variables; acceptable 
fit>0.95, good fit >0.97), standardised root mean square residual (SRMSR; square 
root of the average of the covariance of residuals, good fit<0.08) and root-mean-
squared error of approximation (RMSEA; discrepancy between the model and 
population covariance; good fit <0.06)(27). To estimate the relative quality of a model 
given the data, we calculated information criteria (Akaike information criterion [AIC], 
and Bayesian information criterion [BIC]) of each model. BIC penalises additional 
parameters and free parameters more than AIC. BIC assumes that the true model is 
amongst the candidate models. AIC assumes that the true model is unknown. We 
used different model comparison measures and several goodness-of-fit measures to 
make sure that our model selection was robust to different methods. Since raw AIC 
and BIC values do not have a meaningful scale, we calculated the Akaike and Schwarz 
weights to represent the conditional probability of each model given the data directly 
(28). To have an unbiased estimate, we calculated fit measures (mentioned above) 
iteratively on 1000 bootstrap samples and reported the median of bootstrap results 
with 95% confidence intervals.  
 
Bayesian mediation models 
To calculate how much of the total treatment effect was mediated by intermediate 
variables, we constructed post hoc models for variables involved in the significant 
pathways of a priori models (explained above). Each model included three variables: 
treatment, an intermediate variable and a final outcome. Intermediate and outcome 
variables were the rates of annual change of the following variables: total cholesterol 
level, brain atrophy, EDSS, and Block Design score. Here, we used Bayesian 
multivariate models to report credible intervals, especially for those of cholesterol-
mediated pathways, instead of p-values and confidence intervals to allow an easier 
interpretation of non-significant findings. This enabled testing whether the lack of 
statistically significant cholesterol-mediated effects were because of lack of statistical 
power or there was evidence for the absence of cholesterol-mediation effects of 
simvastatin (29, 30). We used Blavaan package version 0.3-2.283 (31) inside R 
version 3.4.0 (32). In the Bayesian analysis, we considered an effect to be significant 
when the 95% credible interval of a parameter did not cross zero. We discarded the 
first 4,000 (“burn-in” samples) and reported the next 10,000 samples as posterior 
distributions with Markov Chain Monte Carlo method with Stan version 2.16.0 (33). 
We used non-informative uniform priors for Bayesian analyses.  
 
Regional brain atrophy analysis 
To investigate whether the effect of simvastatin was predominant in, and limited to, 
certain brain regions, we carried out univariate mixed-effects models to compare 
regional atrophy rates between trial arms, by adjusting for age, gender, centre, and 
total intracranial volume (34).We summed respective regions from left and right 
hemispheres and constructed linear mixed-effects models for each area (~60 models), 
where the volume of a given area was the dependent variable. Independent variables 
(fixed effects and random effects) were similar to the models used for cognitive and 
clinical outcomes with an additional variable for total intracranial volume to adjust for 
the head size (34) and scanner (1.5 Tesla or 3 Tesla). First, we extracted rates of 
atrophy for those regions that showed a significant rate of change (significant slope, 
p<0.05), after adjustment for multiple comparisons with the false-discovery rate (35). 
With a similar model, we calculated the rate of change within the treatment and 
placebo groups. Therefore, we reported brain regions that showed a significant rate of 
change in the combined treatment and placebo groups as well as separate rates within 
each group. To explore whether the effect of simvastatin on EDSS was mediated by 
regional atrophy, we performed mediation analysis with the following variables: 
1) Predictor variable: treatment (categorical: simvastatin or placebo) 
2) Mediator variable: volume change in the area with the largest effect of 
treatment (transverse temporal gyrus)  
3) Dependent variable: EDSS 
For regional mediation analysis we employed the same methodology as explained 
above (see multivariate analysis). 
We also performed a focused analysis on the volume of medulla oblongata (to capture 
spinal cord related pathology in the absence of spinal cord imaging data), which is 
explained in the Supplemental Material.  
 
Code and material availability 
Computer codes with simulated data for this manuscript can be found at 
https://github.com/armaneshaghi/causalTrialModel.  
 
 
Results 
 
Multivariate analysis: simvastatin effect on clinical outcomes and brain atrophy is 
independent of cholesterol  
 
The cholesterol-independent model, in which simvastatin has a direct effect on the 
clinical and MRI outcome measures, independently by its impact on lowering the 
serum cholesterol levels, was the most likely model (Figures 2A and 2B). The 
cholesterol-independent model showed a better overall fit than the cholesterol-
mediated model. Bootstrapped fit measures for the cholesterol-independent model 
were the following: CFI = 0.95 (95% CI=0.86, 1), SRMR = 0.049 (95% CI= 0.02,0.07), 
RMSEA = 0.11 [90%CI=0, 0.18], AIC = 1800 (95% CI=1719, 1892), BIC = 1860 (95% 
CI=1779, 1952), Akaike weight=0.71, Schwarz weight = 0.46) (Figure 2C). A direct 
comparison by computing Akaike weights (
𝑀𝑜𝑑𝑒𝑙 𝐵 𝐴𝑘𝑎𝑖𝑘𝑒 𝑤𝑒𝑖𝑔ℎ𝑡
 𝑀𝑜𝑑𝑒𝑙 𝐴 𝐴𝑘𝑎𝑖𝑘𝑒 𝑤𝑒𝑖𝑔ℎ𝑡
=  
0.976
0.023
) and Schwarz 
weights (
𝑀𝑜𝑑𝑒𝑙 𝐵 𝑆𝑐ℎ𝑤𝑎𝑟𝑧 𝑤𝑒𝑖𝑔ℎ𝑡
 𝑀𝑜𝑑𝑒𝑙 𝐴 𝑆𝑐ℎ𝑤𝑎𝑟𝑧 𝑤𝑒𝑖𝑔ℎ𝑡
=  
0.704
 0.295
) suggested that the cholesterol independent 
model was considerably more likely than the cholesterol-mediated model (42.24/2.38 
times respectively). 
  
 Within the cholesterol-independent model, simvastatin had a significant direct effect 
on the EDSS (beta=-0.086, standard error =0.044, p=0.047), a direct effect on brain 
atrophy (beta = 0.234, standard error=0.099, p=0.019), and a direct effect on serum 
cholesterol levels (beta = -0.739, standard error=0.076, p<0.001). Other model 
parameters are shown in Figure 2A. Annualised changes in the selected variables are 
shown in the Supplemental Figure 1.  
 
The Bayesian analysis: simvastatin effects on clinical outcomes are independent of 
cholesterol and are partially mediated by brain atrophy 
 
When we calculated how much of the treatment effect was mediated by intermediate 
variables involved in the pathways of the models discussed above, simvastatin effects 
on brain atrophy and disability were confirmed to be independent of cholesterol. In 
particular, simvastatin delayed atrophy directly (treatment➔atrophy, beta=0.32, 95% 
credible interval [CI]=0.09, 0.54), without the mediation of cholesterol 
(treatment➔cholesterol➔atrophy, beta=-0.08, 95% CI=-0.23, 0.07, Figure 2B). Since 
the 95% credible intervals of these two parameters do not overlap, the lack of 
statistical significance for cholesterol-mediated slowing of atrophy is unlikely to be due 
to the lack of statistical power (see Figure 2B).  
Similarly, simvastatin directly delayed disability progression, as measured by the 
EDSS (treatment➔EDSS, beta=-0.139, 95% CI=-0.255, -0.025) without any 
significant mediation from cholesterol (treatment➔cholesterol➔EDSS, beta=0.014, 
95% CI=-0.062,0.093). Since the 95% credible intervals of the direct and indirect 
effects only slightly overlap, this shows that simvastatin effects on EDSS are at least 
partly independent of cholesterol reduction.  
 
When we investigated the possible mediation of brain atrophy, we found that brain 
atrophy significantly mediated 31% of the total treatment effect on the EDSS 
(treatment➔atrophy➔EDSS beta=-0.037, 95% CI=-0.075,-0.010, Figure 2B) and 
35% of the total treatment effect on block design score (treatment➔atrophy➔block 
design, beta=0.33, 95% CI= 0.06, 0.72).  
 
The effect of simvastatin on brain atrophy was predominant on the lateral ventricles 
and transverse temporal gyrus 
In the analysis of the merged treatment and placebo groups several regions showed 
significant rate of change over time (after adjustment for multiple comparisons), the 
fastest of which was the lateral ventricles (1.95% annual expansion [95% confidence 
interval: 1.53%, 2.38%]), followed by the transverse temporal gyrus (estimated annual 
rate= -1.17% [95% confidence interval: -0.88%, -1.46%] (Figure 3). Rates of volume 
loss in the postcentral and precentral gyri, frontal regions, anterior and middle parts of 
the cingulate cortex, precuneus, and thalamus were also significant (which implies 
ongoing volume loss). Figure 3 shows the full list of regions that showed statistically 
significant change over time in the merged analysis of treatment and placebo groups.  
 
When comparing placebo and simvastatin groups, the rates of atrophy were 
numerically slower in several regions in the simvastatin group (Figure 3), but only the 
transverse temporal gyrus showed a significantly faster volume loss in placebo than 
the treated arm (estimated annual rate [95% confidence interval] in placebo group = -
1.58% [95% confidence interval: -1.17%, -1.98%]), simvastatin group = -0.79% [95% 
confidence interval: -0.22%, -1.35%]) (p=0.002). The spatial pattern of focal volume 
loss was similar between the placebo and simvastatin groups on visual inspection and 
qualitative comparison. There was no significant treatment mediation effect of regional 
volume loss in the transverse temporal gyrus on EDSS.  
  
 Discussion 
 
We used multivariate structural equation models to explore test hypothesised causal 
mechanisms that may explain the observed treatment effect of a potential 
neuroprotective drug using the simvastatin trial as a model. In this recent phase 2 trial, 
simvastatin had a direct effect on delaying EDSS worsening and brain atrophy. What 
mediates this beneficial effect of statin treatment remains unclear as both cholesterol-
mediated and cholesterol-independent mechanisms may contribute. In support of the 
former, various studies have reported that elevated circulating cholesterol is 
associated with adverse MS outcomes (36, 37). Therefore, a reduction in blood 
cholesterol through statin treatment may confer benefit. Our study, however, suggests 
that these effects were independent of lowered serum cholesterol and, therefore, does 
not support the hypothesis that simvastatin’s beneficial effects can be attributed to 
serum cholesterol levels and its downstream effects on comorbidities (3). This does 
not rule out a pathogenic role for altered lipid metabolism in MS but suggest that key 
statin-mediated beneficial effector mechanisms may be independent of cholesterol 
lowering.  
 
A cholesterol-independent model, therefore was the most likely option, and mediation 
models suggested that a reduction in the rate of EDSS worsening was partly (31%) 
explained by the treatment effects on brain atrophy, and partly (69%) by a separate 
direct treatment effect. All of these effects were independent of the change in serum 
cholesterol levels. Our mechanistic approach, also known as mediation analysis, goes 
beyond correlation analysis and provides causal evidence of association between two 
variables. This starts by mathematically deconstructing simvastatin effects as 
cholesterol-mediated or cholesterol-independent and allows an indirect understanding 
of whether beneficial simvastatin effects are mediated directly via its effect on 
cholesterol or via other upstream products of the mevalonate pathway (that produces 
cholesterol). Serum cholesterol is only one of the downstream products of the 3-
hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (part of the mevalonate 
pathway), an enzyme that is inhibited by simvastatin. Therefore, the independence of 
treatment effects in MS from the peripheral cholesterol levels points to a role for 
intermediate metabolites downstream of HMG-CoA reductase but upstream of 
cholesterol. Cholesterol-independent (or pleiotropic) products of this pathway include 
isoprenoids that prenylate a variety of key signalling proteins that regulate cell function 
(38) and whose attenuation may have beneficial neuro- and vasculo-protective effects. 
It has been shown in experimental models that simvastatin inhibits brain protein 
isoprenylation (39) .  
 
The central nervous system is highly enriched in cholesterol, especially within myelin, 
and most of the cholesterol of the nervous system is synthetized de novo and is 
independent of blood cholesterol (40). Moreover, intermediate substrates of the 
cholesterol biosynthesis pathway, such as 8,9-unsaturated sterols could deeply 
influence myelin formation and repair (41). Whilst the effect of statins on human brain 
cholesterol levels are unclear, experimental animal data suggests that they have the 
capacity to reduce de novo synthesis and may therefore impact remyelination 
remyelination capacity (40, 42). Although our study was not able to determine 
cholesterol inside the brain, reduced remyelination would have had negative impact 
on patient outcomes. Therefore, the effects of simvastatin inside the brain, if present, 
can only be in the opposite direction of what we have investigated (as beneficial effects 
of simvastatin) and are unlikely to affect our conclusion. Our results suggest that future 
research should focus on changes to upstream intermediate metabolites of the 
cholesterol synthesis pathway rather than the potential anti-comorbidity effects of 
statins in progressive MS (43).  
 
It is possible to speculate that statins can mediate their cholesterol independent effect 
on through impacting on various biological processes. For example, statins are 
reported to have effects on leukocyte adhesion through direct stearic interference of 
the ICAM-1/LFA-1 adhesion molecules (44). In addition, statins can modulate T cell 
immune response (45), inhibit CNS leukocyte migration (46) and neuroinflammatory 
disease (47) in a cholesterol-independent, but isoprenoid dependent, manner. 
However, our previous report of the MS-STAT trial demonstrated no significant effect 
of simvastatin on five immunological markers (IFN-, IL-4, IL-10, IL-17, and CD4 Fox 
P3) suggesting that alternative mechanisms such as neuro- and vasculoprotective 
mechanisms were responsible  (38, 48). Our results for the first time support these 
cholesterol-independent findings in a more neurodegenerative phase of MS 
(secondary progressive MS) with a computational method.  
 
A strength of our study is the investigation of the spatiotemporal pattern of ongoing 
atrophy in patients with secondary progressive multiple sclerosis with very long 
disease duration (21 years). Our regional analysis showed that brain atrophy at the 
whole brain level, rather than the regional level, mediated the treatment effect, 
suggesting that simvastatin has a generalised effect on brain atrophy and does not 
target a single region (e.g., thalamus) (15). Regional susceptibility of neuroanatomical 
areas to neurodegeneration manifests by faster percentage of atrophy rates than that 
of the entire brain. For example, annual percentage volume loss can be up to 4% in 
the hippocampus in Alzheimer’s disease (49, 50), while it is up to 1% for the entire 
brain. In MS, the deep grey matter atrophy rates can be up to 1.5% (15), while the 
whole brain atrophy is 0.6%. In this study, we found that the highest rate of loss was 
in the lateral ventricles, which represent a non-specific, generalised measure of 
atrophy. Unlike patients with early secondary progressive or primary progressive MS, 
none of the deep grey matter nuclei showed a higher rate than total brain rate (the 
thalamic atrophy rate was 0.24%), while the whole brain volume loss on average was 
similar to previous studies (0.65%). Similarly, the medulla oblongata volume, which 
we used as a proxy for spinal cord atrophy (in the absence of spinal cord imaging data) 
did not show significant change. The slower than expected rate of atrophy in these 
structures in patients in this trial (who had a disease duration of more than 20 years) 
suggests a floor-effect at which the decline of these structures may slow down, while 
other structures, such as the transverse temporal gyrus, show a faster rate of atrophy 
in the placebo arm than in the treated group. As we have shown previously (51), 
patients with longer disease duration have lower rates of atrophy in the spinal cord. 
We can speculate that the transverse temporal gyrus, that is the auditory cortex and 
responsible for a “basic” function (52), is spared until later stages of secondary 
progressive MS, which might show a higher rate after exhaustion of other areas. Our 
results are in line with pathological observations that generalised neurodegeneration 
may dominate long-standing secondary progressive MS (53–55), while a more 
selective pattern and ongoing spinal cord atrophy is seen in earlier MS alongside focal 
inflammation that responds to immunomodulation (53, 56).  
 
A major difference between our study and the previous analyses of MS-STAT(2, 8), is 
that we calculated rates of change in imaging and clinical outcomes, rather than 
average differences between treatment groups at each visit which have been reported 
before(2, 8). As Chan et al. reported before, there was a significantly better frontal 
lobe function (as assessed by Frontal Assessment Battery) in the simvastatin group 
as compared to the placebo group at 24 months.  However, this previous report was 
only did not look at the rate of change. In this study we used all three visits (baseline, 
year 1 and year 2), and found that the rate was significant for the block design but not 
for the Frontal Assessment Battery. This is because frontal assessment battery, unlike 
block design, showed a ceiling effect after the first year of this trial, which reduces the 
rate of change. For this reason we only included block design scores in the multivariate 
mechanistic models. Block design evaluates the visuospatial memory and depends on 
fine motor coordination (as it is timed)(57). While there was an association between 
the rate of brain volume loss and block design test, evidence for an indirect treatment 
effect on this cognitive outcome was weaker than EDSS. Our results demonstrate that 
mechanistic multivariate models can quantify and elucidate interrelations of multi-
modal measures in a clinical trial.  
 
It is important to note that our study is limited by its post hoc nature. While pre-planned 
statistical analyses of clinical trials are the gold standard to compare treatments, post 
hoc analyses may nevertheless provide information to generate new hypotheses from 
the wealth of information collected as part of a trial.  
 
In conclusion, we compared mechanistic hypotheses on how a potential 
neuroprotective drug, simvastatin, can influence imaging, clinical, cognitive, and 
patient-reported outcomes through changes in peripheral cholesterol level. We found 
that beneficial effects of simvastatin in secondary progressive MS were independent 
of circulating cholesterol. Simvastatin affected motor functioning directly, and indirectly 
by slowing atrophy rates. A weaker simvastatin effect on visuospatial memory was 
mediated by slowing atrophy rates. Structural equation models can be applied to trials 
of neurodegenerative disorders to provide potential insight into mechanisms and 
quantify the pathways underlying disease worsening and treatment effects.   
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Figure legends 
 
 
Figure 1 legend. Model (A) or cholesterol-mediated model assumes that the 
cholesterol-lowering effect of simvastatin is the cause of the slowing of the brain 
atrophy and disability worsening. Model (B) or cholesterol-independent (or 
pleiotropic) model assumes that the cholesterol-lowering effect of simvastatin is 
independent of its effect on brain atrophy and clinical outcomes. In both models, a 
lower rate of brain atrophy development has an effect on the clinical change, as 
measured by the Expanded Disability Status Scale, Block Design and the Multiple 
Sclerosis Impact Scale-29v2. Additionally, in both models, the physical sub-score of 
Multiple Sclerosis Impact Scale 29v2 (that showed significant effect of treatment) is 
included as the last variable in the cascade of events, because it is a subjective 
patient-reported outcome measure. All the variables are “annualised”, which 
represent annual rates of change between baseline and second-year follow-up visits. 
Each rectangle represents a variable. Arrows represent multivariate regressions, 
where an arrow starts from a predictor and points to the dependent variable. The bar 
plots in the right column compare fit-measures that are shown on the y-axis of each 
of the five bar plots with models (A) and (B) on the x-axis. Blue corresponds to 
cholesterol-mediated model and red to cholesterol-independent model. Fit measures 
suggest that cholesterol-independent model (or model B) was the most likely model 
given data, because it had a higher Akaike and Schwarz weights, higher CFI, lower 
SRMR, and lower RMSEA.   
EDSS; Expanded Disability Status Scale, PBVC; percentage brain volume change, 
MSIS; Multiple Sclerosis Impact Scale. CFI; confirmatory factor index, SRMR; 
standardised root mean square residual, RMSEA; root mean squared error of 
approximation. 
 
 
Figure 2 legend. The section (A) shows the parameter estimates of the winning model, 
which is the model (B) in Figure 1. Each arrow is a regression “path” where the arrow 
starts from the predictor(s) and points to the dependent variable(s). Significant paths 
(p<0.05) are shown with bold arrows, while non-significant paths are thinner. Black 
numbers on each arrow represent regression coefficients and their p-values. Blue 
numbers represent standard errors of the coefficients. The red numbers represent 
standardised coefficients. Section (B) shows the Bayesian post hoc analysis of 
cholesterol-mediated pathway vs direct pathway that does not depend on cholesterol 
to slow brain atrophy. The results confirm that a direct pathway (cholesterol-
independent) slows brain atrophy. The numbers on the left side of the section (B) show 
median of the posterior distribution of the model parameters, and the numbers inside 
parenthesis show 95% credible intervals. The 95% credible intervals of coefficients of 
direct pathway and cholesterol mediated pathways do not overlap, this suggests that 
the lack of significance in cholesterol-mediated pathway is unlikely to be due to a lack 
of statistical power. We used a Bayesian method to ease the interpretation of non-
significant findings and to report credible intervals (rather than the confidence 
intervals). The section (B) also shows Bayesian mediation analyses for brain atrophy 
and EDSS. The direct effect is shown in blue and the mediation effect (or indirect effect) 
is shown in green. The treatment effect on brain atrophy is independent of its effect on 
cholesterol because the 95% credible intervals do not overlap. Brain atrophy mediates 
31% of the treatment effect on EDSS. The section (C) shows mediation analysis for 
other variables. They can be interpreted similarly. PBVC; percentage brain volume 
change, EDSS; Expanded Disability Status Scale, MSIS; Multiple Sclerosis Impact 
Scale (physical subtest). 
Figure 3 Legend: This graph shows the adjusted annual rates of volume loss (or 
expansion for the lateral ventricles) which are calculated from the coefficient of the 
interaction of time and treatment group in the mixed-effects models constructed 
separately for each region. Only regions with significant volume change in the 
combined placebo and treatment analysis are shown (adjusted for multiple 
comparisons with the false-discovery method). Different colours correspond to different 
regions that are shown with the same appearance in left on the T1-weighted scan of 
one of the patients (chosen at random) and, in the right, as bar plots. Two bar plots are 
shown; the above shows the rate of change in the combined analysis of placebo and 
treatment groups on the horizontal axis and different regions on the vertical axis. The 
lower bar plot shows the rate of change for the same areas for placebo and simvastatin 
groups separately. This bar plot shows that only the transverse temporal gyrus shows 
a significant difference in the rate of change when comparing simvastatin and placebo 
groups. The error bars indicate 95% confidence interval of the rate of change. 
  
